Valneva COVID-19 vaccine more effective than AZ
Valneva will seek regulatory approval in the UK and European Union after its COVID-19 vaccine candidate performed well in phase 3 trials
VLA2001, an adjuvanted COVID-19 vaccine from French vaccine company Valneva, has met both its primary endpoints in a phase 3 trial, resulting in higher levels of neutralising antibodies than seen with the AstraZeneca vaccine.
In addition to a strong immune response, VLA2001 also offers a tolerability profile that is statistically significant better than AstraZeneca, with fewer adverse reactions reported especially in the older population.
